Idioma:

The history of MF59® adjuvant: a phoenix that arose from the ashes

O'Hagan, Derek T ; Ott, Gary S ; Nest, Gary Van ; Rappuoli, Rino ; Giudice, Giuseppe Del

Expert review of vaccines, 2013-01, Vol.12 (1), p.13-30 [Periódico revisado por pares]

London: Informa Healthcare

Texto completo disponível

Citações Citado por

Enviar para

Título:
The history of MF59® adjuvant: a phoenix that arose from the ashes
Autor: O'Hagan, Derek T ; Ott, Gary S ; Nest, Gary Van ; Rappuoli, Rino ; Giudice, Giuseppe Del
Assuntos: Adjuvants, Immunologic - adverse effects ; Adjuvants, Immunologic - history ; Adjuvants, Immunologic - therapeutic use ; Adult ; Aged ; Animals ; Biological and medical sciences ; Child ; Child, Preschool ; Clinical Trials as Topic ; emulsion ; Emulsions ; Female ; History, 20th Century ; Human viral diseases ; Humans ; Infant ; Infectious diseases ; Influenza A Virus, H1N1 Subtype - immunology ; influenza vaccine ; Influenza Vaccines - adverse effects ; Influenza Vaccines - history ; Influenza Vaccines - therapeutic use ; Influenza, Human - immunology ; Influenza, Human - prevention & control ; Male ; Medical sciences ; MF59 ; Mice ; pandemic influenza vaccine ; Polysorbates - adverse effects ; Polysorbates - history ; Polysorbates - therapeutic use ; Pregnancy ; Squalene - adverse effects ; Squalene - history ; Squalene - therapeutic use ; vaccine adjuvant ; Viral diseases ; Viral diseases of the respiratory system and ent viral diseases
É parte de: Expert review of vaccines, 2013-01, Vol.12 (1), p.13-30
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Descrição: The first clinical trial of an MF59®-adjuvanted influenza vaccine (Novartis) was conducted 20 years ago in 1992. The product that emerged (Fluad®, Novartis) was licensed first in Italy in 1997 and is now licensed worldwide in 30 countries. US licensure is expected in the coming years. By contrast, many alternative adjuvanted vaccines have failed to progress. The key decisions that allowed MF59 to succeed in such a challenging environment are highlighted here and the lessons that were learned along the way are discussed. MF59 was connected to vaccines that did not succeed and was perceived as a 'failure' before it was a success. Importantly, it never failed for safety reasons and was always well tolerated. Even when safety issues have emerged for alternative adjuvants, careful analysis of the substantial safety database for MF59 have shown that there are no significant concerns with widespread use, even in more 'sensitive' populations.
Editor: London: Informa Healthcare
Idioma: Inglês

Links

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

The history of MF59® adjuvant: a phoenix that arose from the ashes

O'Hagan, Derek T ; Ott, Gary S ; Nest, Gary Van ; Rappuoli, Rino ; Giudice, Giuseppe Del

London: Informa Healthcare

Buscando em bases de dados remotas. Favor aguardar.